Structured evidence table for Carnitine Exercise Recovery Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Carnitine Exercise Recovery Randomized Trial | The results of a prior study confirmed the protective benefits of L-carnitine due to suppression of inflammation, oxidative stress, and increased autophagy (Khedr and Werida). | 1 | Werida Rehab H. (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review |
| Carnitine Exercise Recovery Randomized Trial | Several experimental and clinical studies have suggested that L-carnitine supplementation may confer cardiovascular benefits in CAD patients, including improved cardiac metabolism, reduced oxidative stress, attenuation of inflammatory responses, and enhanced functional outcomes (Da Silva Guimarães et al.; Dastan et al.; Lee et al.; Lee et al.; Pastoris et al.; Singhai et al.; Tarantini et al.; Xue et al.). | 1 | Werida Rehab H. (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review |
| Carnitine Exercise Recovery Randomized Trial | To our best knowledge, this is the first systematic review to address these gaps by synthesizing evidence in CAD patients across mechanistic markers such as oxidative stress, inflammatory mediators, autophagy-related markers and post-PCI myocardial-injury biomarkers together with clinical endpoints such as ventricular arrythmia, mortality and angina. | 1 | Werida Rehab H. (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review |
| Carnitine Exercise Recovery Randomized Trial | 2019 2019 2015 Cardiovascular disease (CVD) is the predominant cause of death worldwide, with a substantial proportion attributable to ischemic heart disease, caused by atherosclerotic coronary artery disease (CAD) (Glovaci et al.; Sarrafzadegan and Mohammadifard). | 1 | Werida Rehab H. (2026) | Therapeutic potential of L-carnitine in coronary artery disease: a systematic review |
| Carnitine Exercise Recovery Randomized Trial | 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
| Carnitine Exercise Recovery Randomized Trial | 1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence (). | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
| Carnitine Exercise Recovery Randomized Trial | Low circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,). | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
| Carnitine Exercise Recovery Randomized Trial | In this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials. | 3 | Wang Xiaolan (2026) | Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults |
Source documents